Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P00790 (
PGA
)
2,475
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Eight male subjects were given pentagastrin by intravenous infusion in doses of 25, 74, 222, 667, and 2000 ng/kg/hr, each dose for 30 min. On another day the same subjects were given the same doses of pentagastrin while
gastric inhibitory polypeptide
(
GIP
) was being infused intravenously in a dose of 2 microgram/kg/hr. At the 222 ng/kg/hr dose of pentagastrin, acid output was significantly lower with
GIP
; at all other doses of pentagastrin, acid output did not differ significantly in tests with and without
GIP
.
Pepsin
output in the tests with and without
GIP
did not differ significantly at any dose of pentagastrin. Plasma concentration of
GIP
, measured by radioimmunoassay, showed a mean +/- SE plateau level of 7.4 +/- 1.4 ng/ml during
GIP
infusion and 0.4 +/- 0.1 ng/ml peak level after a standard meal. We conclude that the increase in blood concentration of
GIP
produced by feeding is probably inadequate to cause significant inhibition of gastric acid or pepsin secretion in man.
...
PMID:Effect of gastric inhibitory polypeptide on pentagastrin-stimulated acid secretion in man. 735 57